TrialHaematologica2024

ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.

Enrique M Ocio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.